Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine-based quadruple versus triple antiemetic regimens for prevention of cisplatin-induced nausea and vomiting during multi-day chemotherapy
ChiCTR1800018424Phase 4Recruiting
- Sponsor
- Ordos Central Hospital
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of olanzapine and dexamethasone in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Ordos Central Hospital. Primary endpoint: Complete response during the overall phase. Started Jan 2018; status: recruiting.
02
Drugs
olanzapinedexamethasone
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR1800018424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018424.